SCHEMBL19451998

SCHEMBL19451998

Cc1cc(-c2cccnc2)nc2c(C(=O)NC3CCCCC3)ccn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 1/20 0.47
CRHR2 Q13324 1/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 3/20 0.46
DYRK1A Q13627 3/20 0.46
WNT1 P04628 2/20 0.46
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CNR2 P34972 1/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CDK2AP1 O14519 1/20 0.42
CHEK1 O14757 1/20 0.42
RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19452192 0.86 CRHR1 (0.47) CRHR1CRHR2ALDH1A1POLBDYRK1A
SCHEMBL21460976 0.86 CRHR1 (0.47) CRHR1CRHR2ALDH1A1POLBDYRK1A
SCHEMBL21483516 0.85 CRHR1 (0.44) CRHR1CRHR2ALDH1A1KDM4EPOLB
SCHEMBL19452178 0.85 CD38 (0.51) CRHR1CRHR2POLBLMNA
SCHEMBL21460970 0.85 CD38 (0.51) CRHR1CRHR2POLBLMNA
SCHEMBL19455189 0.84 ALDH1A1 (0.67) CRHR1CRHR2ALDH1A1KDM4EPOLB
SCHEMBL21460951 0.84 CD38 (0.47) CRHR1CRHR2ALDH1A1POLBDYRK1A
SCHEMBL21461077 0.84 CD38 (0.47) CRHR1CRHR2POLBDYRK1AWNT1
SCHEMBL19451996 0.84 CD38 (0.47) CRHR1CRHR2ALDH1A1POLBDYRK1A
SCHEMBL19452115 0.84 CD38 (0.47) CRHR1CRHR2POLBDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017176962-A1 PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS, INC. (US) 2017-10-12 WO disclosed